Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis

Abstract

Methods: Five children were treated with nine monthly doses of IV CYTX (750–1000 mg/m²/month) and IV MTX (50–300 mg/m²/month) given on the same day. Their clinical and laboratory measurements were collected every other week throughout the nine months.

Results: All children improved dramatically. SLEDAI scores decreased from an average of 13.8 to 4.4, mean (SD) serum creatinine level fell from 100 (60) to 80 (40) µmol/l, and serum albumin rose from 28 (11) g/l to 41 (6) g/l, while the mean (SD) C3 level increased from 0.5 (0.1) g/l to 0.9 (0.4) g/l. Clinical improvement persisted after 4 years' follow up despite discontinuing MTX and CYTX after 9 months. The average daily dose of corticosteroids has been reduced from 27.6 mg/day at the start of treatment to 12.5 mg/day at follow up.

Conclusion: Combined IV MTX and IV CYTX treatment effectively controls recurrent or refractory lupus nephritis in children with significant disease activity after treatment with IV CYTX alone.

Full Text

The Full Text of this article is available as a PDF (222.0 KB).

Figure 1 .

Average SLEDAI score before and after treatment.

Figure 2 .

Change in daily prednisone dose before and after treatment.